Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2022 Annual Meeting of Stockholders (the "Annual Meeting") of Viking Therapeutics, Inc. (the "Company") was held on May 24, 2022. At the Annual Meeting, the Company's stockholders elected the Class I director nominees of the Company, ratified the selection of Marcum LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2022 and approved, on an advisory basis, the compensation of the Company's named executive officers (together, the "Proposals"). Each Proposal is described in detail in the Company's definitive proxy statement for the Annual Meeting that was filed with the U.S. Securities and Exchange Commission on April 7, 2022. As of March 31, 2022, the record date for the Annual Meeting, 77,373,712 shares of the Company's common stock were issued and outstanding. The final votes on the Proposals presented at the Annual Meeting are as follows:

Proposal 1. Election of Class I Director Nominees

Matthew W. Foehr and Charles A. Rowland, Jr. were each elected as Class I directors at the Annual Meeting to serve until the Company's 2025 Annual Meeting of Stockholders, and until his respective successor is duly elected and qualified. The final voting results were as follows:

Director Nominee Votes For Votes Withheld Broker Non-Votes

Matthew W. Foehr 17,067,685 10,728,307 23,407,373 Charles A. Rowland, Jr. 16,320,111 11,475,881 23,407,373

Proposal 2. Ratification of the Selection of the Company's Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Marcum LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2022. The final voting results were as follows:




Votes For    Votes Against   Abstentions   Broker Non-Votes
50,705,637      431,538        66,190             0

Proposal 3. Advisory Vote on Approval of the Compensation of the Named Executive Officers

The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2021, as disclosed in the Company's proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The final voting results were as follows:




Votes For    Votes Against   Abstentions   Broker Non-Votes
25,223,961     1,710,747       861,284        23,407,373

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses